mcarey@rxir.com Immunomic Therapeutics to Present at Biotech Showcase 2023, PharmaJet Partner Immunomic Therapeutics Receives FDA Fast Track Designation for pDNA Vaccine for Skin Cancer, ITI Receives FDA Fast Track Designation for ITI-3000, ITI Announces Presentation on Nucleic Acid-Based UNITE Vaccine Platform at Vaccines Summit 2022. Brian joins the company with over 20 years of experience in cell therapy operations, pharmaceutical manufacturing, and process engineering. ITI-2000 provides an UNITE platform address for HPV+ cancers. November 20, 2020-- Immunomic Therapeutics (ITI) and CoImmune Therapeutics have entered into a license agreement for ITI to use CoImmune's proprietary dendritic cell process for certain ITI cell therapy vaccine programs. Join to connect Immunomic Therapeutics, Inc. Mount Saint Mary's College. Since the Astellas deals, we have nearly doubled our research team to include deeper oncology expertise, including vaccinology, even neoantigen vaccine specialization. SaaS, Android, Cloud Computing, Medical Device), Where the organization is headquartered (e.g. Checkmate-548 was the most recent hope for Opdivo in glioblastoma following the failures, in 2017 and 2019 respectively, of Checkmate-143 in the second-line setting and Checkmate-498 in first-line. Preclinical data is currently being developed to explore whether the UNITE platform may amplify and activate the immune response in highly immunogenic tumor types and be used to create immune responses to tumor types that otherwise do not provoke an immune response. Immunomic Therapeutics Receives FDA Fast Track Designation for ITI-3000 ITI maintains its headquarters in Rockville, Maryland. Immunomic Therapeutics Inc - Company Profile and News UNITE is currently being employed in Phase II clinical trials as a cancer immunotherapy. ITI-2000 HPV+ Tumors. Marques E.T.A., Jr., et al., HIV-1 p55Gag Encoded in the Lysosome-associated Membrane Protein-1 as a DNA Plasmid Vaccine Chimera Is Highly Expressed, Traffics to the Major Histocompatibility Class II Compartment, and Elicits Enhanced Immune Responses. Last Funding Type Venture - Series Unknown. Our Pipeline | Xilio Therapeutics Prior to her role at BTG, she held senior regulatory positions at a variety of companies specializing in therapeutics for oncology, respiratory, neurology, regenerative medicine, orthopedics and cardiovascular disease including Life Cell Corporation (Allergan), Alphatec Spine, Covidien (Medtronic), Lumenis LTD, and C.R. ITI-2000 HPV+ Tumors. San Francisco Bay Area, Silicon Valley), Operating Status of Organization e.g. We believe that these early clinical studies may provide a proof of concept for UNITE in cancer, and if successful, set the stage for future studies, including combinations in these tumor types and others. See Immunomic Therapeutics funding rounds, investors, investments, exits and more. Immunomic Therapeutics Stock Price, Funding, Valuation, Revenue In addition, ITI-1001 represents a far more cost-effective approach. The company was founded in 2005 and is based in Lancaster, Pennsylvania. Mitchell D.A.,Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Jan 2006 - Present17 years 2 months. This day-long event includes an Advocacy Summit Liked by Priscilla Fussell With HLBs support, we are well-positioned to accelerate our efforts in immuno-oncology, in particular glioblastoma multiforme, and rapidly advance other key candidates in our pipeline, including our most recent initiative into infectious diseases with development of our vaccine candidate for COVID-19.. Immunomic Therapeutics, Inc. announced today that it has assumed sponsorship of the Investigational New Drug (IND) application for ITI-1000 from the University of Florida (UF). Eric Winzer - CFO - Immunomic Therapeutics, Inc. | LinkedIn ITIs UNITE platform combines its core lysosomal targeting technology with novel formulation, delivery, and adjuvant complements. A successful transition from cell to cell-free therapy would provide broad validation to the ITI pDNA pipeline. ITIs lysosomal targeting technology is currently being employed in a Phase II clinical trial as a cancer immunotherapy. Claim your Free Employer Profile. Previously, Ms. Harrison served as Senior Vice President, Global Regulatory Affairs and Compliance at BTG International (now Boston Scientific). Concurrent with the financing, five (5) members from HLB Co., LTD will be joining the Immunomic Therapeutics Board of Directors. 2020 Immunomic Therapeutics, Inc. All Rights Reserved. Mr. Stamper holds a Master of Biotechnology Enterprise and Entrepreneurship Degree (MBEE) from Johns Hopkins University, a Master of Science Degree in Biologics Engineering from Purdue University, and a Bachelor of Science Degree in Biochemistry from Indiana University. Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE), which is designed to utilize the bodys natural biochemistry to develop vaccines that generate broad immune responses. The company held a successful pre-IND meeting earlier this year for ITI-1001 and expects to be able to file an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration (FDA) by the end of 2020. Immunomic Therapeutics, Inc. is committed to building, developing and retaining a world-class team. ITI-3000 Merkel Cell Carcinoma - pDNA. Evaluate their financials based on Immunomic Therapeutics's post-money valuation and revenue. Company profile for HLB Co. Ltd. including key executives, insider trading, ownership, revenue and average growth rates. ITI is primarily focused on applying the UNITE platform to oncology, where it could potentially have broad applications, including antigen-derived antibodies as biologics. Of special note are the following publications: To browse the literature, please see the curated list at PubMed. Company profile page for Immunomic Therapeutics Inc including stock price, company news, press releases, executives, board members, and contact information San Francisco Bay Area, Silicon Valley), Operating Status of Organization e.g. ITI is also collaborating with academic centers and biotechnology companies to study the use of UNITE in cancer types of high mortality, including cases where there are limited treatment options like glioblastoma and acute myeloid leukemia. The antigens mainly elicits TH1 response leading to cytokine release, development of cytotoxic CD8 T cells and memory CD4 T cells. Melody Carey Innovative Cellular Therapeutics (ICT) is a clinical-stage, VC-backed cell therapy company based in Rockville, MD. Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE), which is designed to utilize the bo dy's natural biochemistry to develop . mcarey@rxir.com Immunomic Therapeutics Announces First Patient Dosed in Phase I You will receive a reply to confirm the receipt of your application. mkemp@immunomix.com We are delighted to welcome Brian to the Immunomic team, said William Hearl, Ph.D., Immunomic Therapeutics Chief Executive Officer. Glassdoor gives you an inside look at what it's like to work at Immunomic Therapeutics, including salaries, reviews, office photos, and more. The company's immunomodulation platform, LAMP-Vax, enables nucleic acid immunotherapy (DNA or RNA) to utilize the body's natural . Individuals who thrive in our environment are team-oriented, self-motivated, creative, and persistent. Chief Scientific Officer (CSO) Immunomic Therapeutics, Inc. Jun 2019 - Present3 years 9 months. Amy Conrad Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its investigational proprietary technology platform . Glioblastoma Multiforme (GBM) - Immunomic Therapeutics Stock ticker symbol (e.g. immunomic therapeutics crunchbase She succeeds Louise Peltier, Vice President of Regulatory Affairs, who retired on August 31, 2022. Harnessing the immune system to achieve deep and durable clinical responses in cancer. Immunomic Therapeutics' continued investment in Process Development provides value in several ways. People with disabilities who need a reasonable accommodation to apply or compete for employment with Immunomic Therapeutics may request such accommodation(s) by sending an e-mail to: careers@immunomix.com. To demonstrate our dedication to patients and our understanding of the importance of clinical trials, we have created a . It is one of the few malignancies for which incidence approximates prevalence, as patients almost always . They have a proven track record of success in Asia and share our commitment and passion for developing best-in-class therapies for cancer and other serious diseases, said Dr. William Hearl, CEO of Immunomic Therapeutics. Juniper Point ITIs investigational UNITE platform, or UNiversal Intracellular Targeted Expression, works by fusing pathogenic antigens with the Lysosomal Associated Membrane Protein, an endogenous protein in humans, for immune processing. Announces Proposed Public Offering of Common Stock, Northeastern US Companies With Fewer Than 1000 Employees (Top 10K), Companies With Fewer Than 100 Employees (Top 10K), United States Companies that Exited (Top 10K), Greater New York Area Biotechnology Companies. Johns Hopkins startups leverage the university's world-class research assets and the innovation infrastructure of FastForward, our company incubation program. ITI-2000 provides an UNITE platform address for HPV+ cancers. Join to follow . ITIs lysosomal targeting technology is currently being employed in a Phase II clinical trial as a cancer immunotherapy. You can also compare prices and book all best hotels in New Taipei City with one-stop booking service on Trip.com. Contact Email info@immunic.de. This is the Immunomic Therapeutics company profile. ITI Media: 2016;2016:4857869. What is health insurance like at Immunomic Therapeutics. To ensure the most secure and best overall experience on our website, we recommend the latest versions of. 15010 Broschart Dr., Suite 110, Rockville, MD 20850. Copyright 2008-2023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. Our Company Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE ), which is designed to utilize the body's natural biochemistry to develop vaccines that generate broad immune responses Read More Our Focus ITI is . ITI-1000 is being tested in a randomized, blinded, and placebo-controlled phase 2 study in patients with newly-diagnosed glioblastoma (GBM) that is anticipated to close in 2022. SaaS, Android, Cloud Computing, Medical Device), Where the organization is headquartered (e.g. immunomic therapeutics crunchbase. Melissa Kemp Stemming from our UNITE Platform, Immunomic Therapeutics has developed a robust and deep pipeline focused on immunotherapeutics with an emphasis in treating and preventing many oncology indications by leveraging specific characteristics of a type of antigen. The Company has built a pipeline leveraging UNITE with programs in oncology, animal health, infectious disease, and allergy. Over 100 studies have been published on LAMP, ranging from those focused on the fundamental biology of lysosomal associated membrane protein to the immunobiology of novel vaccine candidates. We are looking for passionate individuals who want to create leading edge technology, thrive in an intellectually stimulating environment, and make a difference in healthcare outcomes.